研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,104 件中 181 - 200 件目／全件表示 >>

Relative Dose Intensityに基づく高齢者レンバチニブ投与における全生存期間の検討

横尾健, 酒井規裕, 渡邉雄介, 荒生祥尚, 木村成宏, 阿部寛幸, 薛徹, 上村博輝, 坂牧僚, 上村顕也, 土屋淳紀, 寺井崇二

肝臓 63 ( Suppl.1 ) A302 - A302 2022年4月

肝疾患の小児・成人移行期医療の課題-全人的ケアの確立を目指して成人外来へ受診する可能性をもつ小児脂肪肝の特徴

上村博輝, 上村顕也, 寺井崇二

肝臓 63 ( Suppl.1 ) A169 - A169 2022年4月

医療機関連携急性肝不全ネットワークを円滑に行い生体肝移植にて救命できた急性肝不全昏睡型の1例

武田信峻, 土屋淳紀, 石井結唯, 夏井一輝, 荒生祥尚, 冨永顕太郎, 林和直, 寺井崇二

肝臓 63 ( Suppl.1 ) A265 - A265 2022年4月

本県での肝炎医療コーディネーター養成の現状と活動事例紹介

酒井規裕, 薛徹, 荒生祥尚, 澤栗裕美, 廣川光, 星田和哉, 是永匡紹, 寺井崇二, 新たな手法を用いた肝炎ウイルス検査受検率・陽性者受診率の向上に資する研究班

肝臓 63 ( Suppl.1 ) A243 - A243 2022年4月

【1ページでわかる内科疾患の診療ノート-"あたりまえ"のなかにある大事な視点】(第7章)肝・胆・膵非代償性肝硬変

上村博輝, 寺井崇二

内科 129 ( 4 ) 867 - 871 2022年4月

記述言語：日本語出版者・発行元：(株)南江堂

＜文献概要＞肝硬変は慢性肝疾患の終着点であり,「肝細胞がんに進行することはあっても肝硬変が戻ることはない」というのが従来の考え方であるが,原因とそれに伴う慢性炎症をきちんとコントロールできた場合には,肝硬変/肝線維化の少なくとも一部は可逆性であるという視点から,まず原因の治療,抗炎症療法が重要である.ただし,これらの治療が有効な症例においても肝線維化が改善するには年余の期間が必要である(新犬山分類の線維化の程度が1段階下降するには通常4～5年かかる).この期間,肝硬変患者は常に合併症や発がんのリスクにさらされている.したがって,これらの対策も並行して進める必要がある.さらに原因治療や抗炎症療法に不応性の症例では,肝不全対策や発がん対策(発がんスクリーニングを含む)がいっそう重要となる.詳細は文献1)を参照されたい.

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J00974&link_issn=&doc_id=20220401100086&doc_link_id=issn%3D0022-1961%26volume%3D129%26issue%3D4%26spage%3D867&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0022-1961%26volume%3D129%26issue%3D4%26spage%3D867&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

肝疾患の小児・成人移行期医療の課題-全人的ケアの確立を目指して成人外来へ受診する可能性をもつ小児脂肪肝の特徴

上村博輝, 上村顕也, 寺井崇二

肝臓 63 ( Suppl.1 ) A169 - A169 2022年4月

FALD(フォンタン術後肝障害)の疫学・病態・臨床-診療ガイドラインの確立を目指して先天性心疾患術後の肝線維化進展に影響を及ぼす因子の解析

山崎文紗子, 上村博輝, 寺井崇二

肝臓 63 ( Suppl.1 ) A192 - A192 2022年4月

Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. 国際誌

Atsushi Kimura, Kenya Kamimura, Marina Ohkoshi-Yamada, Yoko Shinagawa-Kobayashi, Ryo Goto, Takashi Owaki, Chiyumi Oda, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

Biochemical and biophysical research communications 596 76 - 82 2022年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model. METHODS: To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily. The physiological changes, histological changes in the liver, vascular structures in the fin, and serum biochemical markers were evaluated in a time-dependent manner after treatment with selective peroxisome proliferator-activated receptor α modulator (pemafibrate), statin (pitavastatin), sodium-glucose cotransporter 2 inhibitor (tofogliflozin), and their combinations. Furthermore, to determine the mechanisms underlying the effects, whole transcriptome sequencing was conducted using medaka liver samples. RESULTS: Histological analyses revealed significant suppression of fat accumulation and fibrotic changes in the liver after treatment with drugs and their combinations. The expression levels of steatosis- and fibrosis-related genes were modified by the treatments. Moreover, the HFD-induced vascular damages in the fin exhibited milder changes after treatment with the drugs. CONCLUSION: The effects of treating various metabolic pathways on the medaka body, liver, and vascular structures of the NASH medaka model were evidenced. Moreover, to our knowledge, this study is the first to report whole genome sequence and gene expression evaluation of medaka livers, which could be helpful in clarifying the molecular mechanisms of drugs.

DOI： 10.1016/j.bbrc.2022.01.086

PubMed

researchmap

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. 国際誌

Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, Hitoshi Yoshiji

Journal of clinical medicine 11 ( 6 ) 2022年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Rifaximin is commonly used for hepatic encephalopathy (HE). However, the effects of long-term treatment for Japanese people are limited. Therefore, this study aimed to investigate the effects and safety of long-term treatment with rifaximin on HE. METHODS: A total of 215 patients with cirrhosis administered with rifaximin developed overt or covert HE, which was diagnosed by an attending physician for >12 months. Laboratory data were extracted at pretreatment and 3, 6, and 12 months after rifaximin administration. The long-term effect of rifaximin was evaluated, and the incidence of overt HE during 12 months and adverse events was extracted. RESULTS: Ammonia levels were significantly improved after 3 months of rifaximin administration and were continued until 12 months. There were no serious adverse events after rifaximin administration. The number of overt HE incidents was 9, 14, and 27 patients within 3, 6, and 12 months, respectively. Liver enzymes, renal function, and electrolytes did not change after rifaximin administration. Prothrombin activity is a significant risk factor for the occurrence of overt HE. The serum albumin, prothrombin activity, and albumin-bilirubin (ALBI) scores were statistically improved after 3 and 6 months of rifaximin administration. Moreover, the same results were obtained in patients with Child-Pugh C. CONCLUSIONS: The long-term rifaximin treatment was effective and safe for patients with HE, including Child-Pugh C.

DOI： 10.3390/jcm11061571

PubMed

researchmap

消化器疾患に対する分化・老化・再生研究の展開 Acute on chronic liver failureに対する老化細胞除去治療の新規開発のための基盤研究

渡邉雄介, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 119 ( 臨増総会 ) A32 - A32 2022年3月